664 related articles for article (PubMed ID: 31505066)
1. Mechanisms of Dupilumab.
Harb H; Chatila TA
Clin Exp Allergy; 2020 Jan; 50(1):5-14. PubMed ID: 31505066
[TBL] [Abstract][Full Text] [Related]
2. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
3. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
Kariyawasam HH
Expert Rev Clin Immunol; 2020 Dec; 16(12):1115-1125. PubMed ID: 33148074
[No Abstract] [Full Text] [Related]
4. Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents.
Licari A; Castagnoli R; Marseglia A; Olivero F; Votto M; Ciprandi G; Marseglia GL
Paediatr Drugs; 2020 Jun; 22(3):295-310. PubMed ID: 32157553
[TBL] [Abstract][Full Text] [Related]
5. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy.
Humbert M; Bousquet J; Bachert C; Palomares O; Pfister P; Kottakis I; Jaumont X; Thomsen SF; Papadopoulos NG
J Allergy Clin Immunol Pract; 2019; 7(5):1418-1429. PubMed ID: 30928481
[TBL] [Abstract][Full Text] [Related]
6. Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.
Benzecry V; Pravettoni V; Segatto G; Marzano AV; Ferrucci S
J Investig Allergol Clin Immunol; 2021 Jun; 31(3):261-263. PubMed ID: 32732182
[No Abstract] [Full Text] [Related]
7. Dupilumab: Basic aspects and applications to allergic diseases.
Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
[TBL] [Abstract][Full Text] [Related]
8. Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.
Eschenbacher W; Straesser M; Knoeddler A; Li RC; Borish L
Immunol Allergy Clin North Am; 2020 Nov; 40(4):539-547. PubMed ID: 33012318
[TBL] [Abstract][Full Text] [Related]
9. Commonality of the IL-4/IL-13 pathway in atopic diseases.
Gandhi NA; Pirozzi G; Graham NMH
Expert Rev Clin Immunol; 2017 May; 13(5):425-437. PubMed ID: 28277826
[TBL] [Abstract][Full Text] [Related]
10. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice.
Tauber M; Apoil PA; Richet C; Laurent J; De Bonnecaze G; Mouchon E; Cassagne M; Marguery MC; Hegazy S; Konstantinou MP; Severino M; Uthurriague C; Giordano-Labadie F; Didier A; Paul C
Br J Dermatol; 2019 Jun; 180(6):1551-1552. PubMed ID: 30633329
[No Abstract] [Full Text] [Related]
11. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab for the treatment of adolescents with atopic dermatitis.
Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab for the treatment of asthma.
Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
[TBL] [Abstract][Full Text] [Related]
15. Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders.
Hait EJ; McDonald DR
Clin Rev Allergy Immunol; 2019 Oct; 57(2):213-225. PubMed ID: 30206783
[TBL] [Abstract][Full Text] [Related]
16. Introduction to "allergic inflammation".
Nakayama T
Immunol Rev; 2017 Jul; 278(1):5-7. PubMed ID: 28658548
[No Abstract] [Full Text] [Related]
17. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
[TBL] [Abstract][Full Text] [Related]
19. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.
Bakker DS; van der Wal MM; Heeb LEM; Giovannone B; Asamoah M; Delemarre EM; Drylewicz J; Nierkens S; Boyman O; de Bruin-Weller MS; Thijs JL; van Wijk F
J Invest Dermatol; 2021 Aug; 141(8):1943-1953.e13. PubMed ID: 33610558
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab: First Global Approval.
Shirley M
Drugs; 2017 Jul; 77(10):1115-1121. PubMed ID: 28547386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
